Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (Nasdaq: GANX) is a clinical-stage biotechnology company whose news flow is closely tied to the development of its lead drug candidate, GT-02287, and to progress in its broader allosteric small molecule pipeline. The company focuses on next generation allosteric therapies targeting neurodegenerative diseases, rare genetic disorders and oncology, with a primary emphasis on Parkinson’s disease.
News about Gain Therapeutics frequently covers clinical milestones for GT-02287, including updates from its Phase 1 and Phase 1b studies in people with Parkinson’s disease with or without a GBA1 mutation. Press releases have detailed safety and tolerability findings, exploratory biomarker data such as reductions in glucosylsphingosine (GluSph) in cerebrospinal fluid, and observations related to Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores. These items provide insight into how the company interprets GT-02287’s potential disease-modifying effects and mechanism of action.
Investors and observers can also expect regular announcements on preclinical research and scientific presentations. Gain Therapeutics reports data from preclinical models that explore GCase modulation, mitochondrial and lysosomal health, and neuroprotection in Parkinson’s disease. Poster presentations at scientific meetings, such as Neuroscience conferences and Parkinson’s-focused congresses, are common subjects of the company’s news releases.
Additional news items include corporate updates and financial disclosures, such as quarterly financial results, capital raises, changes in board composition, and shareholder meeting outcomes. The company also issues notices about participation in investor conferences, key opinion leader (KOL) events, and webinars that discuss biomarkers, clinical endpoints and emerging data from GT-02287 studies.
For readers following GANX, the news page provides a centralized view of clinical trial progress, scientific data, regulatory and corporate developments, and event participation related to Gain Therapeutics’ efforts in allosteric small molecule drug development.
Gain Therapeutics (Nasdaq: GANX) announced breakthrough results from a study on its STAR compounds, GT-02287 and GT-02329, for treating Gaucher and GBA1 Parkinson's Disease. Conducted at the University of Maryland, the study demonstrated significant increases in GCase protein levels in iPSC-derived dopaminergic neurons and reductions in phosphorylated α-synuclein. These findings reveal a potential new approach for neurodegenerative disorders, showing a 129% increase in GCase enzyme levels. The company plans to initiate IND-enabling studies soon, promising hope for patients with alpha synucleinopathies.
Gain Therapeutics (Nasdaq: GANX) announced participation at the 12th Annual Jefferies London Healthcare Conference on November 16-19, 2021. CEO Eric Richman will present on November 17 from 9:20 to 9:55 a.m. GMT. Investors can engage in one-on-one meetings either in-person or virtually. The presentation will focus on Gain's innovative drug development strategies targeting neurodegenerative diseases and lysosomal storage disorders through its proprietary SEE-Tx™ platform. For more details, visit Gain’s official website.
Gain Therapeutics, Inc. (Nasdaq: GANX) announced that its management team will present at key medical conferences, including The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Webinars on November 10, 2021, and The Society of Neuroscience Annual Meeting on November 9, 2021. The webinars aim to showcase advancements in Parkinson’s research, featuring topics like drug discovery and brain-penetrant allosteric regulators. These sessions will provide insights into ongoing research supported by the foundation. For registration and further information, visit the respective conference websites.
Gain Therapeutics has established a Scientific Advisory Board (SAB) to enhance its research efforts in neurodegenerative diseases and lysosomal storage disorders. Dr. Luca Benatti has been appointed as the chair, joined by esteemed members including Dr. Samuel Broder and Dr. Joanne Taylor. These experts bring decades of significant industry experience to shape the company's clinical strategies as it progresses its lead program in Parkinson’s Disease toward trials. Gain aims to redefine drug discovery through its innovative SEE-Tx™ platform.
Gain Therapeutics, Inc. (Nasdaq: GANX) recently appointed Matthias Alder as Chief Operating Officer to enhance its operational capabilities and prepare for clinical trials of its lead program targeting Gaucher and Parkinson's Diseases, expected in 2022. Alder brings over 25 years of industry experience, previously serving as Chief Business Officer at Autolus Therapeutics. CEO Eric Richman expressed confidence in Alder's ability to scale Gain's platform and expand partnerships. The company focuses on allosteric binding sites using its innovative SEE-Tx™ discovery platform to address neurodegenerative diseases.
Gain Therapeutics, Inc. (Nasdaq: GANX) will participate in the Cantor Virtual Global Healthcare Conference from September 27th-30th, showcasing its innovative approach to targeting allosteric binding sites for neurodegenerative diseases. CEO Eric Richman will present on September 30, from 8:00 to 8:30 a.m. ET, with a webcast available for interested investors. Gain Therapeutics aims to redefine drug discovery using its SEE-Tx™ platform, unlocking new treatment options for challenging disorders.
Gain Therapeutics (Nasdaq: GANX) announced that CEO Eric Richman will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 20-23, 2021. The presentation is scheduled for September 22 from 1:15 to 1:55 p.m. ET. Investors can participate via webcast and one-on-one meetings. Gain Therapeutics focuses on optimizing allosteric binding sites in treatments for neurodegenerative diseases.
Gain Therapeutics, focused on neurodegenerative diseases, announced a presentation by Dr. Manolo Bellotto on their allosteric regulators for GM1 Gangliosidosis and Morquio B Disease. The presentation will take place on September 14, 2021, at 2:00 PM PT/5:00 PM ET during the GM1 Virtual Community Conference. These diseases are linked to mutations in the GLB1 gene, leading to toxic substrate accumulation. Gain's STARs aim to potentially treat neurological symptoms, marking a significant advancement in the field.
Gain Therapeutics (Nasdaq: GANX) reported positive topline data from its study on two STAR compounds, GT-02287 and GT-02329, aimed at treating Gaucher Disease and GBA1 Parkinson’s Disease. Conducted at the University of Maryland, the study showed increased GCase protein levels, enhanced enzymatic activity, and decreased α-synuclein in neurons. The company plans to present comprehensive data at an upcoming Michael J. Fox Foundation webinar and initiate IND-enabling studies in Q4 2021, further supporting its Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) platform.
Gain Therapeutics (GANX) announced positive topline data from a study on its compounds GT-02287 and GT-02329 for treating Gaucher and GBA1 Parkinson's Disease. The study showed increased GCase protein levels and activity, along with a decrease in toxic α-synuclein levels. Conducted in collaboration with the University of Maryland School of Medicine, findings will be presented in a webinar organized by the Michael J. Fox Foundation. The company plans to initiate IND-enabling studies for these treatments in Q4 2021.